Company intelligence / Profile preview

LightIntegra Technology

Vancouver, British Columbia, Canadaprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

ThromboLUX has demonstrated utility as a rapid, noninvasive optical test to determine platelet activation status and size distribution in blood products. It enables healthcare providers to match the right platelet units to specific patient needs—nonactivated platelets for cancer patients and activated platelets for trauma/surgery—reducing ineffective transfusions and minimizing platelet refractoriness. The technology aims to improve patient outcomes and reduce healthcare costs by optimizing blood product utilization.

Therapeutic areas: Hematology
Modalities: DeviceDiagnostic test (ThromboLUX)
Industry: Pathology

Partnerships

Canadian Blood Services R&D labs (originated from this collaboration)

Beyond the preview

Go deeper on LightIntegra Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LightIntegra Technology.

Explore the full profile